Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
701 - Successful In Vivo Re-Administration of AAV with the Use of Two-Step AAV Injection Add To Itinerary May 6, 2016, 6:00 PM - 8:00 PM Authors Anna Majowicz, Harald Petry, Valerie Ferreira Research, uniQure N.V., Amsterdam, Netherlands Disclosures A. Majowicz: 1; Commercial Interest i.e. Company X; uniQure. 1; What was received? i.e. Honorarium; Salary. 1; For what role? i.e. Speaker; Employee. Abstract Introduction: The major challenge for a successful re-administration of AAV vectors is the presence of neutralizing antibodies (NABs) directed against AAV developed after the first administration of AAV vectors. Those serotype-specific neutralizing antibodies directed towards the viral capsid proteins prevent efficient gene transfer with AAV of the same serotype. The generation of a humoral immune response does not permit the use of “vector of choice” more than once which is a concern for life-long disorders for which re-administration has to be considered. Currently different methods are being explored in order to circumvent the presence of anti-AAV NABs at re-administration. One of those methods is based on the principle of antibody adsorption in AAV-based gene delivery. It was first observed in mice by Scallan et al. who reported that the administration of AAV vectors in the presence of empty AAV capsids significantly reduced the neutralization of AAV vectors by anti-AAV circulating NAB (Scallan et al. 2006). Additionally, Mingozzi et al. have also shown in mice and non-human primates that injection of therapeutic AAV vector together with empty AAV capsids allows liver transduction in the presence of high titers of anti-AAV NABs (Mingozzi et al. 2013). Goal: The goal of our study was to decrease the anti-AAV NABs to a level that would allow successful repeated gene delivery with the same AAV serotype. Study design and results: We have designed an approach to decrease the levels of circulating NABs in vivo by mean of anti-AAV NABs adsorption. In our study, for the re-administration of AAV in the presence of anti-AAV NABs, a two-step AAV vector injection was used. The first dose of AAV vector was used as a “decoy” AAV that captured circulating anti-AAV NABs. To allow a proper binding of circulating anti-AAV NABs by “decoy” AAVs, we delayed the second AAV injection. In our proof of concept experiments, mice were initially immunized with AAV5-GFP. Two weeks later the re-administration of AAV5 was performed. The re-administration procedure consisted of a first “decoy” AAV5-GFP injection followed by an injection with AAV5-hSEAP. In a first experiment, mice were injected with a “decoy” AAV5-GFP followed by AAV5-hSEAP at 30, 60 or 120 minutes after the first injection. A significant decrease of total anti-AAV5 antibody levels after injection of the “decoy” AAV5-GFP vector was observed. In the second study, we used a similar procedure with a 30 min time frame between ”decoy” AAV5-GFP and AAV5-hSEAP injection, using three different doses of the “decoy” AAV5-GFP. The decrease of total anti-AAV5 antibodies 30 min after “decoy” AAV5-GFP injection was inversely proportional to the dose of the “decoy” AAV5-GFP used and to the hSEAP activity levels that were achieved after AAV5-hSEAP injection. Conclusions:Based on hSEAP transgene activity levels, we were able to determine a cut-off level of anti-AAV5 antibodies that allow a successful re-administration of the AAV5. Overall, the two-step AAV injection approach as such is promising for AAV re-administration.www.abstractsonline.com/pp8/#!/4077/p...
Phase I Open Label Liver-Directed Gene Therapy Clinical Trial for Acute Intermittent Porphyria.ac.els-cdn.com/S0168827816301982/1-s2... Background & Aims Acute intermittent porphyria (AIP) results from porphobilinogen deaminase (PBGD) haploinsufficiency, which leads to hepatic over-production of the neurotoxic heme precursors porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) and the occurrence of neurovisceral attacks. Severe AIP is a devastating disease that can only be corrected by liver transplantation. Gene therapy represents a promising curative option. The objective of this study was to investigate the safety of a recombinant adeno-associated vector expressing PBGD (rAAV2/5-PBGD) administered for the first time in humans for the treatment of AIP. Methods In this phase I, open label, dose-escalation, multicenter clinical trial, four cohorts of 2 patients each received a single intravenous injection of the vector ranging from 5x1011 to 1.8x1013 genome copies/kg. Adverse events and changes in urinary PBG and ALA and in the clinical course of the disease were periodically evaluated prior and after treatment. Viral shedding, immune response against the vector and vector persistence in the liver were investigated. Results Treatment was safe in all cases. All patients developed anti-AAV5 neutralizing antibodies but no cellular responses against AAV5 or PBGD were observed. There was a trend towards a reduction of hospitalizations and heme treatments, although ALA and PBG levels remained unchanged. Vector genomes and transgene expression could be detected in the liver one year after therapy. Conclusion rAAV2/5-PBGD administration is safe but AIP metabolic correction was not achieved at the doses tested in this trial. Notwithstanding, the treatment had a positive impact in clinical outcomes in most patients. Lay summary Studies in an acute intermittent porphyria (AIP) animal model have shown that gene delivery of PBGD to hepatocytes using an adenoassociated virus vector (rAAV2/5-PBG) prevent mice from suffering porphyria acute attacks. In this phase I, open label, dose-escalation, multicenter clinical trial we show that the administration of rAAV2/5-PBGD to patients with severe AIP is safe but metabolic correction was not achieved at the doses tested; the treatment, however, had a positive but heterogeneous impact on clinical outcomes among treated patients and 2 out of 8 patients have stopped hematin treatment. Volledig art.via link.
The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency www.sciencedirect.com/science/article... In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease Huntington’s disease (HD) is a progressive autosomal dominant disease, caused by a CAG repeat expansion in the HTT gene, resulting in an expanded polyglutamine stretch at the N-terminal of the huntingtin protein. An important event in HD pathogenesis appears to be the proteolysis of the mutant protein, which forms N-terminal huntingtin fragments. These fragments form insoluble aggregates and are found in nuclei and cytoplasm of affected neurons where they interfere with normal cell functioning. Important cleavage sites are encoded by exon 12 of HTT. A novel approach is Htt protein modification through exon skipping, which has recently been proven effective both in vitro and in vivo. Here we report proof-of-concept of AON 12.1 in vivo using the YAC128 mouse model of HD. Our results support and encourage future longitudinal studies exploring the therapeutic effects of sustained infusions in the YAC128 mouse model.www.sciencedirect.com/science/article... Adeno-associated virus (AAV) vectors in cancer gene therapy www.cchem.berkeley.edu/schaffer/2016%... David Schaffer
Perspective on the Road toward Gene Therapy for Parkinson's Disease www.ncbi.nlm.nih.gov/pmc/articles/PMC...
Improvement of AAV-mediated liver transduction efficacy by regional administration in Macaca fascicularis europepmc.org/abstract/MED/28285544
Via Vita(Thx!): www.iex.nl/Forum/Topic/1342839/uniQur... MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain www.nature.com/gt/journal/vaop/ncurre...
#ASGCT17 $QURE abstract 395 - Successful Repeated Hepatic Gene Delivery in Non-Human Primates Achieved with AAV5 by Use of Immune Adsorption www.abstractsonline.com/pp8/#!/4399/p... #ASGCT17 $QURE Novel AAV Vector Reservoirs: Peripheral Blood Cells and Hematopoietic Progenitors www.abstractsonline.com/pp8/#!/4399/p... #ASGCT17 $QURE Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human Primates www.abstractsonline.com/pp8/#!/4399/p... #ASGCT17 $QURE AAV5-miHTT Gene Therapy Demonstrates Broad Vector Distribution and Strong Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model www.abstractsonline.com/pp8/#!/4399/p... #ASGCT17 $QURE Detection of AAV Vector DNA and Transgene RNA in Liver Tissue by Fluorescent In Situ Hybridization www.abstractsonline.com/pp8/#!/4399/p...
Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system www.nature.com/articles/s41434-018-00...
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. www.sciencedirect.com/science/article...
Virally Mediated Overexpression of Glial-Derived Neurotrophic Factor Elicits Age- and Dose-Dependent Neuronal Toxicity and Hearing Loss (Bas Blits, $QURE ) www.liebertpub.com/doi/10.1089/hum.20... #GDNF
Artificial microRNAs targeting C9ORF72 have the potential to reduce accumulation of the intra-nuclear transcripts in ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) patients ac.els-cdn.com/S2162253119300149/1-s2... $QURE
Inhibition of Semaphorin3A Promotes Ocular Dominance Plasticity in the Adult Rat Visual Cortex. link.springer.com/article/10.1007%2Fs...
flosz schreef op 4 februari 2019 20:03 :
Artificial microRNAs targeting C9ORF72 have the potential to reduce accumulation of the intra-nuclear transcripts in
ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) patients
ac.els-cdn.com/S2162253119300149/1-s2... $QURE
+ Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy $QURE www.cell.com/molecular-therapy-family...
$QURE #ASGCT19 APRIL29-MAY2,WASHINGTON,D.C. Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5 Neutralizing Antibodies (NABs) Titers in Minipig Serum Do Not Reflect Levels of Anti-AAV5 NABs Titers in Their Cerebrospinal Fluid (CSF) AAV-based therapies generated promising pre-clinical results translating into phase I clinical trials for several neurodegenerative diseases. However, it remains unclear whether naturally acquired pre-existing systemic immunity to AAV would affect the therapeutic efficacy of AAV vectors delivery to the Central Nervous System (CNS). To address this question, we investigated the levels of pre-existing anti-AAV5 NABs in serum and in CSF in a cohort of minipigs. Thirty matched serum and CSF samples from wild type minipigs were analyzed for the presence of anti-AAV5 NABs. While serum samples of minipigs had detectable levels of anti-AAV5 NABs that varied between a titer of 2 (negative) to 256 (positive), CSF samples of all the minipigs were found negative for the presence of anti-AAV5 NABs. Hence, no detectable anti-AAV5 NABs were detected in CSF of animals that had systemic pre-existing anti-AAV5 NAB titers up to 256. In order to translate our data to clinic, an anti-AAV5 NABs prevalence study was performed using serum of healthy donors (n=350). In this cohort, 88% of the subjects had anti-AAV5 NABs titers below 256. We have previously reported that serum anti-AAV5 NAB titers up to 340 in humans and as high as 1030 in primates did not interfere with the therapeutic efficacy of intravenously administered AAV5 vector. Combined with the current data, we conclude that the risk for reduced therapeutic efficacy of intrathecal or intraparenchymal administration of therapeutic AAV5 vectors by pre-existing neutralizing AAV5 antibodies is very low. Further studies are needed to determine the local and systemic induction and persistence of anti-AAV5 NABs titers following intrathecal or intraparenchymal administration of AAV5 vectors to assess the possibility of re-administration of AAV5-based gene delivery.www.asgct.org/global/documents/asgct1... annualmeeting.asgct.org/UserFiles/fil... $QURE #ASGCT19 APRIL29-MAY2,WASHINGTON,D.C. Improving AAV Quality Attributes and Process Robustness Through Molecular Redesign The manufacturing of recombinant AAV relies significantly on the underlying production technologies to support the robustness and scalability of clinical grade AAV material. To date two main production platforms are utilized to generate clinical grade rAAV material. One is the chemical transient transfection of HEK293 cells and the other is utilizing the baculovirus expression vectors to deliver genetic material to insect cells. The baculovirus production system has been shown to be capable of large scale rAAV manufacturing (500L) in stirred tank reactors while maintaining the high quality of the rAAV attributes. That said, large scale processes require a significant improvement in process robustness. Process robustness is dependent on the timing, quantity and quality of the precursor substrates where scaling of the processes can lead to difficulty in controlling these key parameters. Here we will highlight the results from molecular biology approaches in attaining higher process stability. Key improvements were obtained for the % full capsids (minimally 70% full, up from 30%), crude lysed bulk titers (2-fold improvement) and a process that is significantly less sensitive to the starting and raw materials used for production. In conclusion, molecular engineering of the BEVS constructs facilitated significant process-related improvements and robustness. www.asgct.org/global/documents/asgct1... annualmeeting.asgct.org/UserFiles/fil...
In-depth characterization of a Mifepristone regulated expression system for AAV5-mediated gene therapy in the liver www.cell.com/molecular-therapy-family...
Cerebral organoids: a human model for AAV capsid selection and therapeutic transgene efficacy in the brain. www.cell.com/molecular-therapy-family...
Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. www.nature.com/articles/s41434-020-01...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
881,78
+0,30%
EUR/USD
1,0779
-0,09%
FTSE 100
7.952,62
+0,26%
Germany40^
18.505,40
+0,07%
Gold spot
2.234,24
0,00%
NY-Nasdaq Composite
16.379,46
-0,12%
Stijgers
Dalers